SABR demonstrates significant efficacy in older patients with kidney cancer
The study achieved 100% local control and cancer-specific mortality rates with stereotactic ablative body radiotherapy.
How APPs can bridge the gap in urologist shortages
In this episode, Janelle Bunce, PA-C, highlights the role that advanced practice providers can play in filling the gaps created by the growing workforce shortages in urology.
Study identifies 11 gene mutations linked to aggressive prostate cancer
This is the largest prostate cancer study that examined the exome, according to the researchers, who believe their findings can potentially inform the makeup of panels used for genetic testing in prostate cancer.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Clinical navigators may improve genomic testing rates among Black patients with prostate cancer
Data showed that the proportion of Black patients referred for genomic testing increased from 19% to 58% after the implementation of the precision medicine navigator.
Treatment starts in trial of theranostic for 177Lu-PSMA-617–ineligible mCRPC
The phase 1/2 COMBAT study examining the novel theranostic 64Cu/67Cu-SAR-Bombesin.
2 Clarke Drive Cranbury, NJ 08512